Last reviewed 2026-04-20 · How we verify

UMEC

UmeC is a small molecule drug that works by interacting with a specific target in the body.

UmeC is a small molecule drug developed by Glaxo Group in England, currently owned by the same company. Unfortunately, there is limited information available on its target, drug class, or approved indications. As a result, its mechanism of action, safety considerations, and commercial status are unknown. Further research is needed to understand the potential benefits and risks of UmeC. Its status as a patented or generic medication also remains unclear.

At a glance

Mechanism of action

Imagine UmeC as a key that fits into a lock in the body. When it binds to this lock, it triggers a series of events that can help to treat a particular condition. However, without more information, it's difficult to say exactly how UmeC works or what condition it's intended to treat.

Approved indications

• Asthma
• Chronic bronchitis
• Chronic obstructive lung disease
• Pulmonary emphysema

Common side effects

• Nasopharyngitis
• Upper respiratory tract infection
• Cough
• Arthralgia
• Pharyngitis
• Viral upper respiratory tract infection
• Myalgia
• Abdominal pain upper
• Toothache
• Contusion
• Tachycardia

Serious adverse events

• Atrial fibrillation
• Pneumonia
• Supraventricular tachycardia
• Supraventricular extrasystoles
• Sinus tachycardia
• Idioventricular rhythm
• Depression

Key clinical trials

• Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma (PHASE4)
• Evaluation of Supraclavicular Brachial Plexus Blocks at Various Volumes: Impact on Optic Nerve Sheath Diameter (NA)
• VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
• To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD (PHASE4)
• A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma (PHASE3)
• 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation (PHASE4)
• Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma (PHASE3)
• Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma (PHASE3)

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.